Ng Ying Kin uses neurochemical analyses to identify peripheral biological markers for various psychiatric disorders.

Patricia Boksa conducts research on pregnancy and birth complications as risk factors for the later development of schizophrenia.

Marc Laporta, MD, develops international collaborative ventures  in the area of emergencies and disasters for the Americas.

Bruno Giros characterizes the neurobiology of schizophrenia and develops improved genetic animal models of this illness.

As a clinician, Johanne Renaud holds the title of medical chief for the youth section of the Douglas Institute’s Depressive Disorders Program.

Natalie Grizenko is medical director with the mandate of integrating research, teaching and clinical excellence throughout the program.

Martin Lepage uses using functional magnetic resonance imaging (fMRI) to study memory deficits in patients with schizophrenia.

Ridha Joober developed a pharmaco-genetic profile of schizophrenia that may lead to earlier diagnosis and more effective treatment.

Camillo Zacchia is Senior advisor, Mental Health Education Office (MHEO) at the Douglas Institute.

Alain Brunet, PhD, studies risk factors and develops effective treatments for PTSD, such as early intervention and reconsolidation blockade.